Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Emtriva opvejer risiciene ved behandling af hiv- 1- inficerede voksne og børn, når det anvendes i kombination med andre antiretrovirale midler.
The Committee for Medicinal Products for Human Use (CHMP) decided that Emtriva’ s benefits are greater than its risks for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.